{'fraction_non_alphanumeric': 0.0358814352574103, 'fraction_numerical': 0.0078003120124804995, 'mean_word_length': 5.42, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Femoropopliteal atherosclerosis: do drug-eluting stents improve outcome?

Paclitaxel-eluting devices, including drug-eluting balloons (DEBs) and drug-eluting stents (DESs), have been shown to be safe and effective in several randomized trials. This technology greatly improved the prognosis of patients with obstructive disease in the femoral and popliteal districts, as well as the results of percutaneous angioplasty. Despite a high procedural success rate (over 90%), simple balloon angioplasty has been taxed with a significant restenosis rate in the short term and mid-term. Many studies confirmed a restenosis rate of 50% after 1 year.